Global status report on road safety
Tamitza Toroyan
Abstract
Tamitza Toroyan
Abstract
Objective. To determine the safety and efficacy of prednisone in patients with symptomatic heart failure (HF) and hyperuricemia. Methods. Prednisone therapy was administered for a short time to 191 symptomatic HF patients with hyperuricemia (serum uric acid > 7 mg/dl). Results. Prednisone significantly reduced serum uric acid by 2.99 mg/dl (p < 0.01) and serum creatinine by 0.17 mg/dl (p < 0.01). These favorable effects were associated with a remarkable increase in urine output, improvement in renal function, and improvement in clinical status. Conclusion. Prednisone can be used safely in symptomatic HF patients with hyperuricemia.
OpenAlex reports 1096 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective. To determine the safety and efficacy of prednisone in patients with symptomatic heart failure (HF) and hyperuricemia. Methods. Prednisone therapy was administered for a short time to 191 symptomatic HF patients with hyperuricemia (serum uric acid > 7 mg/dl). Results. Prednisone significantly reduced serum uric acid by 2.99 mg/dl (p < 0.01) and serum creatinine by 0.17 mg/dl (p < 0.01). These favorable effects were associated with a remarkable increase in urine output, improvement in renal function, and improvement in clinical status. Conclusion. Prednisone can be used safely in symptomatic HF patients with hyperuricemia.
Key concepts: Hyperuricemia, Prednisone, Medicine, Creatinine, Uric acid, Internal medicine, Renal function, Urine